{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T21:47:28Z","timestamp":1794692848100,"version":"4.9.1"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.atherosclerosis.2026.120636","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T07:23:22Z","timestamp":1768202602000},"page":"120636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Seventeen years to change practice: will the 2025 ESC\/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?"],"prefix":"10.1016","volume":"413","author":[{"given":"Kausik K.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-1120","authenticated-orcid":false,"given":"Florian","family":"Kronenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120636_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","author":"Mach","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib3","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib4","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib5","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib6","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1093\/eurheartj\/ehab312","article-title":"SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions","volume":"42","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib7","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide cross-sectional observational Study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib10","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","article-title":"Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study","volume":"31","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib11","article-title":"Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study","volume":"31","author":"Brandts","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib12","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/cvr\/cvaf155","article-title":"Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study","volume":"121","author":"Li","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib13","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib14","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial","author":"Ballantyne","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib15","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","article-title":"Impact of obicetrapib on major adverse cardiovascular events in high-risk patients: a pooled analysis","volume":"86","author":"Nicholls","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2022.1876","article-title":"Statin eligibility for primary prevention of cardiovascular disease according to 2021 European Prevention Guidelines compared with other international Guidelines","volume":"7","author":"Mortensen","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5334\/gh.1154","article-title":"World Heart Federation Cholesterol Roadmap 2022","volume":"17","author":"Ray","year":"2022","journal-title":"Glob Heart"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib20","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S2213-8587(16)30057-2","article-title":"Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study","volume":"4","author":"Brownrigg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib21","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","article-title":"Comparative cardiovascular benefits of bempedoic acid and Statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100278","article-title":"Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins","volume":"8","author":"Bays","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","article-title":"Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial","volume":"320","author":"Rubino","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/ehjqcco\/qcac009","article-title":"Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study","volume":"8","author":"Ray","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.002","article-title":"Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study","volume":"366","author":"Ray","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib30","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib31","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: a patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib34","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/cvr\/cvaf078","article-title":"RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: a drug-target Mendelian randomization study","volume":"121","author":"Gagnon","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib35","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jacc.2025.04.049","article-title":"Safety and lipid-lowering efficacy of inclisiran monotherapy in patients without ASCVD: the VICTORION-Mono randomized clinical trial","volume":"86","author":"Taub","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib36","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib37","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after Acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib38","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib39","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib41","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1093\/eurheartj\/ehae576","article-title":"Intensive early and sustained lowering of non-high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry","volume":"45","author":"Schubert","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib42","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jacc.2025.02.007","article-title":"Early ezetimibe initiation after myocardial infarction protects against later cardiovascular outcomes in the SWEDEHEART registry","volume":"85","author":"Leosdottir","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib43","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/eurheartj\/ehab718","article-title":"Combination lipid-lowering therapy as first-line strategy in very high-risk patients","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib44","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.atherosclerosis.2023.04.012","article-title":"Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society","volume":"374","author":"Kronenberg","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib47","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11883-024-01187-6","article-title":"Lipoprotein(a): from causality to treatment","volume":"26","author":"Kronenberg","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib49","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib50","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/eurheartj\/ehw152","volume":"37","author":"Nordestgaard","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib51","first-page":"1129","article-title":"Canadian Cardiovascular Society Guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib52","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.jacl.2024.03.001","article-title":"A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice","volume":"18","author":"Koschinsky","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib54","first-page":"e596","article-title":"ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American college of Cardiology\/American Heart Association task force on clinical practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib55","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119218","article-title":"The Brussels international declaration on Lipoprotein(a) testing and management","volume":"406","author":"Kronenberg","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120447","article-title":"Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis","volume":"409","author":"Morton","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib58","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","article-title":"Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees","volume":"33","author":"Kronenberg","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib59","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/eurjpc\/zwae032","article-title":"Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research","volume":"31","author":"Kamstrup","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120468","article-title":"The test that pays for itself: why we can no longer afford to ignore Lp(a)","volume":"409","author":"Boren","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib62","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib63","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib64","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib65","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib67","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1093\/eurheartj\/ehaf297","article-title":"Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database","volume":"46","author":"MacDougall","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106843","article-title":"Daring to dream: targeting lipoprotein(a) as a causal and risk-enhancing factor","volume":"194","author":"Koschinsky","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib69","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower Lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib71","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce Lipoprotein(a) in cardiovascular disease","volume":"387","author":"O'Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib72","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran - a long-duration small interfering RNA targeting Lipoprotein(a)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib73","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/jama.2024.21957","article-title":"Zerlasiran-A small-interfering RNA targeting lipoprotein(a): a phase 2 randomized clinical trial","volume":"332","author":"Nissen","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib74","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of Lipoprotein(a): a randomized clinical trial","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib76","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1161\/CIRCULATIONAHA.123.065520","article-title":"Randomized trial for evaluation in secondary prevention efficacy of combination Therapy-Statin and eicosapentaenoic acid (RESPECT-EPA)","volume":"150","author":"Miyauchi","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib77","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib78","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","article-title":"Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome","volume":"390","author":"Stroes","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib79","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib80","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCULATIONAHA.122.057443","article-title":"Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context","volume":"147","author":"Ntsekhe","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib81","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib82","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and left ventricular ejection fraction following Doxorubicin treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib83","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib84","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1074248418821721","article-title":"Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, Single-Blind, placebo-controlled trial","volume":"24","author":"Nabati","year":"2019","journal-title":"J Cardiovasc Pharmacol Therapeut"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib85","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib86","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41591-024-02905-y","article-title":"Development and validation of a new algorithm for improved cardiovascular risk prediction","volume":"30","author":"Hippisley-Cox","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2022.10.013","article-title":"Comparative effects of low-dose Rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers","volume":"81","author":"Laffin","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib88","series-title":"Crossing the quality chasm: a new health System for the 21st century","year":"2001"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib89","first-page":"65","article-title":"Managing clinical knowledge for health care improvement, yearb. Med","author":"Balas","year":"2000","journal-title":"Inform"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib90","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1258\/jrsm.2011.110180","article-title":"The answer is 17 years, what is the question: understanding time lags in translational research","volume":"104","author":"Morris","year":"2011","journal-title":"J R Soc Med"},{"key":"10.1016\/j.atherosclerosis.2026.120636_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.fhj.2025.100452","article-title":"Creating system-wide change in medicine: the role of implementation science in achieving scale and adoption","volume":"12","author":"Barry","year":"2025","journal-title":"Future Healthc J"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502600002X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502600002X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:08:08Z","timestamp":1770286088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502600002X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":91,"alternative-id":["S002191502600002X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120636","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seventeen years to change practice: will the 2025 ESC\/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120636"}}